Citations

Clear

367 citation(s) found for "Su, Pan".

Prognostic and predictive utility of DNA damage response (DDR) aberrations detected in cell-free DNA (cfDNA) in metastatic castration-resistant prostate cancer (mCRPC).
Hauser, Christine , Tan, Winston , Du, Pan , Ng, Nicole , Bukczynska, Patricia , Foroughi, Siavash , Graham, Lisa-Jane K., Jia, Shidong , Fettke, Heidi , Kwan, Edmond M. , Dai, Chao , Zheng, Tiantian , Wang, Amy , Horvath, Lisa G. , Mahon, Kate Lynette , Kohli, Manish , Azad, Arun

Mayo Clinic

Journal of Clinical Oncology | February 16, 2022 | Volume: 40 | Issue: 6_suppl | Pages: 153-153

10.1200/jco.2022.40.6_suppl.153 Get It

153 Background: The prognostic significance of DDR alterations in mCRPC remains unclear, with conflicting data from prior reports. Whether DDR alterations are predictive of outcomes with therapeutic agents other than PARP inhibitors in mCRPC is also poorly understood. With increasing use of molecular profiling in mCRPC, understanding the full prognostic and predictive utility of plasma DDR alterations is paramount. Methods: A next-generation sequencing Predicine liquid biopsy assay was used to profile cfDNA and germline DNA in 407 mCRPC patients (pts) from two independent international cohorts (n=162 Australia, n=245 US). DDR genes profiled were BRCA2, ATM, BRCA1, MLH1 and MSH2. Kaplan-Meier survival estimates and multivariable Cox regression analyses were used to assess associations between DDR alterations and clinical outcomes including PSA response rate (PSA RR), progression-free survival and overall survival (OS). Results: Median age was 74 (IQR 67-79), with median follow up 74 months and median OS 23 months. 65/407 (16%) harboured pathogenic DDR alterations, including 21 patients with ³1 alteration. Frequency of genomic aberrations are shown in the table. BRCA2 alterations were further classified as heterozygous loss (66%), homozygous loss (14%), monoallelic mutation (11%) and biallelic mutation/loss of heterozygosity (9%). Aberrations in any DDR gene, ATM, MLH1 + MSH2 or BRCA2 were associated with shorter OS on univariable analysis, but only any DDR or BRCA2 aberration remained significant upon adjusting for clinical prognosticators and ctDNA fraction (Table). Pre-treatment BRCA2 aberration was associated with significantly shorter OS and lower PSA RR compared to BRCA2 wt for pts receiving an AR pathway inhibitor (ARPI) (18 vs 32 months, p=0.006; 36 vs 60%, p=0.04 respectively) but not for taxane chemotherapy (17 vs 20 months, p=0.3; 45 vs 66, p=0.1 respectively). Conclusions: Detection of an aberration in any DDR gene or BRCA2 was an independent poor prognostic factor across 2 large independent cohorts of mCRPC patients. Intriguingly, patients with a BRCA2 alteration appeared to have worse outcomes with ARPI but not chemotherapy, suggesting predictive utility of DDR profiling. Our data collectively speak to the potential role of DDR alterations, in particular BRCA2, as prognostic and/ or predictive biomarkers in mCRPC.[Table: see text]
Age-based assessment of cell-free DNA genomic profiles in metastatic castration-resistant prostate cancer (mCRPC).
Knox, Andrea, Hauser, Christine , Bukczynska, Patricia , Ng, Nicole , Foroughi, Siavash , Graham, Lisa-Jane K., Tan, Winston , Du, Pan , Jia, Shidong , Fettke, Heidi , Mahon, Kate Lynette , Zheng, Tiantian , Dai, Chao , Horvath, Lisa G. , Kohli, Manish , Azad, Arun , Kwan, Edmond M. , Wang, Amy

Mayo Clinic

Journal of Clinical Oncology | February 16, 2022 | Volume: 40 | Issue: 6_suppl | Pages: 150-150

10.1200/jco.2022.40.6_suppl.150 Get It

150 Background: With the evolving use of targeted therapies exploiting genomic vulnerabilities in mCRPC, screening patients for sensitizing alterations is of increasing relevance. However, the influence of age on the detection of relevant genomic alterations is incompletely understood. In this study, we compared the cell-free DNA (cfDNA) profiles of younger (age <70) versus older (age ≥70) men with mCRPC and assessed the relative prognostic impact of common genomic alterations. Methods: A next-generation sequencing-based Predicine cfDNA assay was used to profile 276 mCRPC patients from two independent international cohorts. The frequency of genomic alterations across age categories was compared using the chi-squared test, while circulating tumour DNA fraction (ctDNA%) was compared using the Mann–Whitney U test. Cox proportional hazards analysis with interaction testing was used to assess the association between age, genomic alteration and overall survival. Results: The median age of the combined cohort was 72 years (IQR 66-78), with 170 (62%) patients ≥70 years old. Despite differences in baseline characteristics (poorer performance status in older patients, higher Gleason score and de novo metastatic disease in younger patients), there was no significant difference in ctDNA% (median 22% vs 30%, p=0.6). We observed similar frequencies of genomic alterations across the 10 most commonly aberrant genes, including AR (<70 vs ≥70: 46% vs 49%, p=0.6), TP53 (40% vs 36%, p=0.6), BRCA2 (29% vs 21%, p=0.13) and PTEN (39% vs 35%, p=0.5). This similarity persisted when analysing mutations and copy number alterations in isolation. While driver alterations in both age categories were strongly associated with unfavourable outcomes (Table), an exploratory analysis revealed that copy number gain in PIK3CA may have a worse prognostic impact in younger men ( p for interaction = 0.03), with a lesser effect observed in AR gain ( p = 0.1) and MYC gain ( p = 0.1). Conclusions: The genomic profiles of pertinent alterations between younger and older men are comparable. Certain genomic alterations may carry a worse prognosis in younger men. Patients should be considered for precision medicine assessment and directed therapies, regardless of age. [Table: see text]
3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC
Yan, Yuqian , Shao, Jingwei , Ding, Donglin , Pan, Yunqian , Tran, Phuc , Li, Hongyu , Huang, Haojie , Huang, Rui , Yan, Wei , Wang, Zhenyu

Mayo Clinic

Chemical Communications | January 26, 2022 | Volume: 58 | Issue: 14 | Pages: 2383-2386

10.1039/d1cc06525d | PMID 35080528 Get It

In this study, we discovered 3-aminophthalic acid as a new ligand of cereblon (CRBN) E3 ubiquitin ligase and developed a phthalic acid-based O’PROTAC for ERG destruction, expanding the pool of ligands for development of PROTACs, especially O’PROTACs.
Accelerated versus watchful waiting strategy of kidney replacement therapy for acute kidney injury: a systematic review and meta-analysis of randomized clinical trials
Chen, Jui‐Yi , Pan, Heng‐Chih , Hsieh, Chih-Chieh , Hsu, Tsuen‐Wei , Huang, Yun‐Ting , Huang, Tao‐Min , Huang, Chun-Te , Kashani, Kianoush , Kashani, Kianoush B , Chen, Yung‐Ming , Shiao, Chih‐Chung , Wu, Vin‐Cent

Mayo Clinic

Clinical Kidney Journal | January 12, 2022 | Volume: 15 | Issue: 5 | Pages: 974-984

10.1093/ckj/sfac011 | PMID 35498901 Get It

ABSTRACT Background Critically ill patients with severe acute kidney injury (AKI) requiring kidney replacement therapy (KRT) have a grim prognosis. Recently, multiple studies focused on the impact of KRT initiation time [i.e., accelerated versus watchful waiting KRT initiation (WWS-KRT)] on patient outcomes. We aim to review the results of all related clinical trials. Methods In this systematic review, we searched all relevant randomized clinical trials from January 2000 to April 2021. We assessed the impacts of accelerated versus WWS-KRT on KRT dependence, KRT-free days, mortality and adverse events, including hypotension, infection, arrhythmia and bleeding. We rated the certainty of evidence according to Cochrane methods and the GRADE approach. Results A total of 4932 critically ill patients with AKI from 10 randomized clinical trials were included in this analysis. The overall 28-day mortality rate was 38.5%. The 28-day KRT-dependence rate was 13.0%. The overall incident of KRT in the accelerated group was 97.4% and 62.8% in the WWS-KRT group. KRT in the accelerated group started 36.7 h earlier than the WWS-KRT group. The two groups had similar risks of 28-day [pooled log odds ratio (OR) 1.001, P = 0.982] and 90-day (OR 0.999, P = 0.991) mortality rates. The accelerated group had a significantly higher risk of 90-day KRT dependence (OR 1.589, P = 0.007), hypotension (OR 1.687, P &lt; 0.001) and infection (OR 1.38, P = 0.04) compared with the WWS-KRT group. Conclusions This meta-analysis revealed that accelerated KRT leads to a higher probability of 90-day KRT dependence and dialysis-related complications without any impact on mortality rate when compared with WWS-KRT. Therefore, we suggest the WWS-KRT strategy for critically ill patients.
Discovery of small molecule guanylyl cyclase A receptor positive allosteric modulators
Sangaralingham, S. Jeson , Whig, Kanupriya , Peddibhotla, Satyamaheshwar , Kirby, R. Jason, Sessions, H, Maloney, Patrick , Hershberger, Paul, Mose-Yates, Heather, Hood, Becky , Vasile, Stefan , Pan, Shuchong, Zheng, Ye , Malany, Siobhan , Burnett, John C. , Maloney, Patrick R , Sangaralingham, S. Jeson

Mayo Clinic

Proceedings of the National Academy of Sciences | December 20, 2021 | Volume: 118 | Issue: 52 | Pages: No page available

10.1073/pnas.2109386118 | PMID 34930837 Get It

Significance The particulate guanylyl cyclase A receptor (GC-A), via its endogenous cardiac-derived hormones atrial natriuretic peptide (ANP) and b-type natriuretic peptide (BNP), plays a pivotal role in maintaining intravascular volume, arterial pressure, cardiovascular structure, function, and, more recently, metabolic homeostasis. As such, therapies to potentiate GC-A signaling via peptide augmentation have yielded promising results in clinical trials. A major breakthrough in GC-A therapeutics would be a small molecule that sensitizes the GC-A receptor to endogenous ANP or BNP, which to date does not exist. Here, we report the development of an orally bioavailable, small molecule positive allosteric modulator of GC-A that exhibits therapeutic activity in human hypertension and heart failure ex vivo.
Anti-NMDAR encephalitis presenting after immature teratoma resection
Chetram, Deandra Kimberly, Pan, Kelsey , Elfasi, Aisha , Chetram, Deandra , Markham, Merry Jennifer

Mayo Clinic

BMJ Case Reports | November 19, 2021 | Volume: 14 | Issue: 11 | Pages: e244637

10.1136/bcr-2021-244637 | PMID 34799390 Get It

This is a case of a young woman who developed neurological and psychiatric symptoms 3 days after resection of an immature teratoma. She was diagnosed with anti-NMDA receptor encephalitis via positive serum antibody titres, which was later confirmed with cerebrospinal fluid antibody titres. Given her cancer diagnosis, she underwent treatment with bleomycin, etoposide and cisplatin chemotherapy in addition to 5 days of high-dose steroids (1 g of intravenous methylprednisolone) for the encephalitis. This treatment regimen led to significant clinical improvement 3 weeks after completion of one cycle of chemotherapy.
Differences in management and treatment of traumatic adult pan brachial plexus injuries: a global perspective regarding continental variations
Shin, Alexander Y. , Desai, Ketan, Fox, Michael , Spinner, Robert J. , Shin, Alexander Y , Socolovsky, Mariano , Wang, Shufeng

Mayo Clinic

Journal of Hand Surgery (European Volume) | August 19, 2021 | Volume: 47 | Issue: 1 | Pages: 40-51

10.1177/17531934211039677 | PMID 34407694 Get It

An expert opinion study was designed to query five countries and six brachial plexus surgeons regarding the demographics, mechanisms of injury, evaluation, timing of surgery, reconstructive strategies and controversies in adult traumatic pan brachial plexus injuries. Variations in assessing outcomes, management of neuropathic pain and future considerations were elucidated. Clear differences in regional demographics, mechanisms of injury, patient evaluation and treatment strategies were identified. The role of phrenic nerve and contralateral C7 transfer, acute use of free functioning muscle transfers, root reimplantation and amputation/myoelectric prosthetic fitting were regional/surgeon dependent. Comparison of outcomes across regions requires an understanding of the regional nuances of patient demographics, injury mechanisms, preferred reconstructive strategies and how outcomes are measured. Future studies are required to allow accurate regional comparisons.
Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
Shao, Jingwei , Yan, Yuqian , Ding, Donglin , Wang, Dejie , He, Yundong , Pan, Yunqian , Kharbanda, Anupreet , Li, Hongyu , Huang, Haojie , Huang, Rui , Yan, Wei

Mayo Clinic

Advanced Science | August 16, 2021 | Volume: 8 | Issue: 20 | Pages: No page available

10.1002/advs.202102555 | PMID 34397171 Get It

AbstractDNA‐binding proteins, including transcription factors (TFs), play essential roles in various cellular processes and pathogenesis of diseases, deeming to be potential therapeutic targets. However, these proteins are generally considered undruggable as they lack an enzymatic catalytic site or a ligand‐binding pocket. Proteolysis‐targeting chimera (PROTAC) technology has been developed by engineering a bifunctional molecule chimera to bring a protein of interest (POI) to the proximity of an E3 ubiquitin ligase, thus inducing the ubiquitination of POI and further degradation through the proteasome pathway. Here, the development of oligonucleotide‐based PROTAC (O'PROTACs), a class of noncanonical PROTACs in which a TF‐recognizing double‐stranded oligonucleotide is incorporated as a binding moiety of POI is reported. It is demonstrated that O'PROTACs of lymphoid enhancer‐binding factor 1 (LEF1) and ETS‐related gene (ERG), two highly cancer‐related transcription factors, successfully promote degradation of these proteins, impede their transcriptional activity, and inhibit cancer cell growth in vitro and in vivo. The programmable nature of O'PROTACs indicates that this approach is also applicable to destruct other TFs. O'PROTACs not only can serve as a research tool but also can be harnessed as a therapeutic arsenal to target DNA binding proteins for effective treatment of diseases such as cancer.
Neoadjuvant Study of Niraparib in Patients With HER2-Negative, BRCA-Mutated Resectable Breast Cancer
Liu, Minetta C. , Irie, Hanna Y. , Santa‐Maria, Cesar A. , Reeves, James E., Pan, Peng , Shan, Ming , Tang, Yongqiang , Graham, Julie , Hazard, Sebastien , Isakoff, Steven J. , Spring, Laura , Han, Hyo S , Hamilton, Erika , Santa-Maria, Cesar Augusto , Pan, Peng, Graham, Julie, Ellisen, Leif W.

Mayo Clinic

No container title available | August 6, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-711810/v1 Get It

Abstract This study evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30% reduction from baseline) by MRI was 90.5% and 40.0% (6/15) of patients who only received niraparib (2–6 cycles) had pathological complete response. No new safety signals were identified and high niraparib intratumoral concentration was observed.
Comparison of synchronization between left bundle branch and his bundle pacing in atrial fibrillation patients: An intra‐patient‐controlled study
Sheng, Xia , Pan, Yiwen , Yu, Chan, Wang, Bei , Zhang, Pei , Li, Jing , Zhang, Jiefang , Chen, Shiquan , Wang, Min , Sun, Yaxun , Jiang, Dongmei , Yang, Ying , Ye, Yang , Cha, Yong‐Mei , Pan, Yi-Wen , Zhang, Jie-Fang , Sun, Ya-Xun , Fu, Guo-Sheng

Mayo Clinic

Pacing and Clinical Electrophysiology | August 2, 2021 | Volume: 44 | Issue: 9 | Pages: 1523-1531

10.1111/pace.14331 | PMID 34337768 Get It

AbstractBackgroundHis bundle pacing (HBP) is a physiological pacing strategy to preserve the electrical synchrony of ventricular conduction and left ventricular (LV) function. Left bundle branch pacing (LBBP) has emerged as an alternative physiological pacing technique.ObjectiveTo evaluate cardiac electrical and mechanical synchrony comparing LBBP and HBP in patients with permanent atrial fibrillation (AF).MethodsConsecutive patients with symptomatic bradycardia and AF were enrolled from January to June of 2019. The cardiac electrical and mechanical synchrony in different pacing mode were evaluated at baseline and after implantation.ResultsBoth HBP and LBBP were performed in 20 patients. LBBP significantly widened the QRS duration compared with the intrinsic conduction (113.2 ± 14.5 vs. 96.5 ± 16.2 ms; p = .01), while HBP did not (104.5 ± 22.3 vs. 96.5 ± 16.2 ms; p = .12). Both LBBP and HBP patients had similar LV myocardial strain measurements for the mechanical synchrony evaluation without significant change compared with baseline. There was no significant difference in right ventricular synchrony measurement between LBBP and HBP. Compared to HBP, LBBP had less interventricular synchrony (IMVD, 14.7 ± 9.2 vs. 3.1 ± 12.7 ms, p < .01; Ts‐LV‐RV, 37.9 ± 10.7 vs. 18.5 ± 10.8 ms, p < .001).ConclusionsAlthough LBBP's a physiological pacing mode can achieve a similar cardiac electrical and mechanical synchronization when compared to HBP, LBBP results in modest delay in RV activation, and the clinical implication remains to be studied.